Virometix: Anergis And Virometix Announce Research Collaboration To Use Synthetic Virus-Like Particles For Ultra-Fast Allergy Immunotherapy

Anergis SA, a company developing Contiguous Overlapping Peptides (COPs) for ultra-fast allergy immunotherapy, and Virometix AG, a company developing a new generation of vaccines and immunotherapeutic drugs, announced today that they have entered into a research collaboration.